Bio Green Med Solution (BGMS) Net Income towards Common Stockholders (2010 - 2026)
Bio Green Med Solution (BGMS) posted quarterly Net Income towards Common Stockholders of -$217000.0 for Q1 2026, down 167.9% year-over-year from $319581.8 in Q1 2025, and up 97.87% quarter-over-quarter from -$10.2 million in Q4 2025.
Powered by 
Analysis
Bio Green Med Solution (BGMS) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Bio Green Med Solution (BGMS) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$217000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 167.9% year-over-year to -$217000.0; the TTM figure through Mar 2026 stood at -$14.2 million (down 70.46% YoY), while the FY2025 annual figure was -$14.1 million, down 25.69% from the prior year.
- Net Income towards Common Stockholders rose to -$217000.0 in Q1 2026 per BGMS's latest filing, from -$10.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$81000.0 in Q1 2025 and bottomed at -$10.2 million in Q4 2025.
- Historically, Net Income towards Common Stockholders has averaged -$4.1 million across 5 years, with a median of -$4.2 million in 2022.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 878.83% — and 2025, when it soared 97.25%.
- Bio Green Med Solution's Net Income towards Common Stockholders stood at -$7.5 million in 2022, then rose by 28.76% to -$5.3 million in 2023, then surged by 42.64% to -$3.1 million in 2024, then slumped by 233.22% to -$10.2 million in 2025, then jumped by 97.87% to -$217000.0 in 2026.
- Business Quant data shows BGMS's Net Income towards Common Stockholders at -$217000.0 in Q1 2026, -$10.2 million in Q4 2025, and -$2.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.56 Bn | 133.71 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 87.63 Bn | 79.64 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.65 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 60.24 Bn | 55.10 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.13 Bn | 44.13 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.46 Bn | 35.36 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.86 Bn | 32.56 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.00 Bn | 27.16 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Bio Green Med Solution | 4.68 Mn | 886,595.10 | 79,000.00 | -425,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -425,000.00 |
| Mar 31, 2026 | -217,000.00 |
| Dec 31, 2025 | -10.17 Mn |
| Sep 30, 2025 | -2.50 Mn |
| Jun 30, 2025 | -1.34 Mn |
| Mar 31, 2025 | -81,000.00 |
| Dec 31, 2024 | -3.05 Mn |
| Sep 30, 2024 | -1.96 Mn |
| Jun 30, 2024 | -3.26 Mn |
| Mar 31, 2024 | -2.95 Mn |
| Dec 31, 2023 | -5.32 Mn |
| Sep 30, 2023 | -6.08 Mn |
| Jun 30, 2023 | -5.50 Mn |
| Mar 31, 2023 | -5.85 Mn |
| Dec 31, 2022 | -7.47 Mn |
| Sep 30, 2022 | -5.25 Mn |
| Jun 30, 2022 | -4.63 Mn |
| Mar 31, 2022 | -4.16 Mn |
| Dec 31, 2021 | 9.13 Mn |
| Sep 30, 2021 | -6.68 Mn |